Compass Pathways announced Tuesday that its experimental depression treatment successfully achieved its primary objectives in a comprehensive late-stage clinical trial, causing the company’s stock price to surge nearly 30 percent.
The pharmaceutical company tested its therapy, known as COMP360, across two extensive clinical trials that included over 1,000 participants suffering from treatment-resistant depression.
The innovative treatment utilizes psilocybin, a psychedelic substance, and represents a potential breakthrough as a short-duration, periodic treatment option that could replace daily antidepressant medications.
According to the company’s findings from the most recent trial, participants who received two higher-strength doses administered three weeks apart demonstrated significantly greater improvement in their depression symptoms over a six-week period compared to those who received smaller doses.
